RESUMEN
Objective To investigate the sleep quality and influencing factors in patients with stable myasthenia gravis (MG).Methods From September 2015 to February 2017,151 cases of stable MG were enrolled in the department of neurology,West China Hospital,Pittsburgh sleep quality index (PSQI) was used to evaluate their sleep quality;Spearman analysis was used to analyze the influencing factors (clinical data,quality of life,anxiety and depression).Results Spearman test analysis showed that PSQI was positively correlated with age,duration,myasthenia gravis quality of life 15 (MG-QOL15),Hamilton Anxiety Scale 14 (HAMA14),Hamilton Depression Scale 24 (HADA24) (P ＜ 0.05).Stepwise regressionanalysis further revealed that life quality was the best predictor of reduced sleep quality (t =3.161,P =0.002),followed by anxiety (t =2.495,P =0.014) and age (t =2.356,P =0.020).Conclusions There are many influencing factors of stable MG wnich more attentions should be paid on.
RESUMEN
18F fluorodeoxyglucose, as a kind of tracer, has its limitations in positron emission tomography/computed tomography (PET/CT). 18F-fluorothymidine (18F-FLT) is a kind of new tracer. The value of 18F-FLT in diagnosis of tumor, tumor staging and assessment of therapeutic effects was reviewed in this article.
RESUMEN
Objective To investigate the effect of lamivudine (LAM) on serum interferon (IFN)-γ and interleukin (IL)-4 levels in patients with chronic hepatitis B(CHB). Methods Serum IFN-γ and IL-4 levels were measured with enzyme-linked immunosorbent assay (ELISA) in 66 CHB patients at baseline and 3, 6, 9 and 12 months after LAM treatment respectively. And 20 healthy volunteers served as healthy control. The comparision of pretreatment and post-treatment was done using t test and numberation data were analyzed by non parametric rank sum test. Results In HBeAg positive patients, the serum level of IFN-γ was (21.03±4.44) ng/L in complete response group, which was higher than partial response group [(13.85±3.92) ng/L] and non-response group [(10.63± 3.11) ng/L] (t=7.56,t=11.87, both P<0.01). Take that IFN-γ is 15.66 ng/L as boundry patients with high baseline IFN-γ level showed much higher complete response rate (31.0% vs 8.7%, x2 =8.391, P<0.01) and lower non-response rate (13.8% vs 52.2%,x2=4. 256, P<0.01) than those with low baseline IFN-γ levels. After LAM treatment, the IFN-γ/IL-4 ratios in complete response patients were approximate or even higher than those in healthy group, whereas the IFN-γ/ IL-4 ratios of patients with partial response and non response were lower than those in healthy group. In HBeAg negative patients, the IFN-γ/IL-4 ratios increased slowly but didn't reach the same levels of healthy group. Conclusions It is suggested that LAM treatment can increase IFN-γ release and reduce IL-4 release in CHB patients. The response type to LAM therapy is associated with the recovery of T helper cell (Th) 1/Th2 balance post-treatment and pretreatment IFN-γ levels.